July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Genetic factors associated with response to aflibercept therapy for exudative age -related macular degeneration
Author Affiliations & Notes
  • Yoichi Sakurada
    Ophthalmology, University of Yamanashi, Chuo, Yamanashi, Japan
  • Seigo Yoneyama
    Ophthalmology, University of Yamanashi, Chuo, Yamanashi, Japan
  • Wataru Kikushima
    Ophthalmology, University of Yamanashi, Chuo, Yamanashi, Japan
  • Atsushi Sugiyama
    Ophthalmology, University of Yamanashi, Chuo, Yamanashi, Japan
  • Mio Matsubara
    Ophthalmology, University of Yamanashi, Chuo, Yamanashi, Japan
  • Naohiko Tanabe
    Ophthalmology, University of Yamanashi, Chuo, Yamanashi, Japan
  • Fumihiko Mabuchi
    Ophthalmology, University of Yamanashi, Chuo, Yamanashi, Japan
  • Hiroyuki Iijima
    Ophthalmology, University of Yamanashi, Chuo, Yamanashi, Japan
  • Footnotes
    Commercial Relationships   Yoichi Sakurada, None; Seigo Yoneyama, None; Wataru Kikushima, None; Atsushi Sugiyama, None; Mio Matsubara, None; Naohiko Tanabe, None; Fumihiko Mabuchi, None; Hiroyuki Iijima, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2963. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yoichi Sakurada, Seigo Yoneyama, Wataru Kikushima, Atsushi Sugiyama, Mio Matsubara, Naohiko Tanabe, Fumihiko Mabuchi, Hiroyuki Iijima; Genetic factors associated with response to aflibercept therapy for exudative age -related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2019;60(9):2963.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the association between genetic variants and response to aflibercept therapy for exudative age-related macular degeneration (AMD) during 12-month follow-up.

Methods : All patients were performed monthly follow-up and received 3 monthly intravitreal aflibercept injection (IAI). Additional IAI was performed if residual or recurrent exudation was seen on spectral-domain optical coherence tomography (SD-OCT). We genotyped seven genetic variants associated with exudative AMD.

Results : One-hundred sixty-six patients (mean age:75.5±8.2, male/female:118/48, typical AMD/Polypoidal choroidal vasculopathy:83/83) were included in this study. Additional treatment was required for 112(67.5%) patients during 12-month follow-up period. Patients without requiring retreatment were significantly younger than patients requiring retreatment(P=1.2×10-3). After adjusting age and gender, T allele frequency at ARMS2 A 69S(rs10490924) and C allele frequency at CFH(rs1329428) were significantly lower in patients without requiring retreatment than in patients requiring retreatment(P=1.4×10-5 and 5.9×10-3, respectively). Number of additional injection was significantly different among ARMS2 A69S genotypes and CFH(rs1329428) genotypes (P=3.5×10-5 and 6.0×10-3, respectively) after adjusting age and gender. There were no genetic variants associated with visual outcomes at 12-month.

Conclusions : In as-needed aflibercept therapy for exudative AMD, ARMS2 and CFH variants were associated with retreatment and number of additional injections.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×